Try our Advanced Search for more refined results
Life Sciences - October, 2015
326 articles
- High Court Told 7th Circ. Was Too Easy On Class Cert. Bid
- Ex-BNY Manager Accused Of Insider Trading Seeks Probation
- Perrigo, Mylan Denied Competing Requests In $27B Bid Fight
- Pa. Court Won't Rethink Upholding $4M Topamax Verdict
- Patheon Defeats JV-Partner's Antitrust Suit Over Rival Buy
- Genentech Beats Avastin Off-Label Injury Claims In Texas
- Valeant Taps Kirkland & Ellis Atty As Pharmacy Crisis Grows
- Potential Pfizer-Allergan Deal Reignites Inversion Scrutiny
- Adderall Purchasers Push For Cert. In Pay-For-Delay Suit
- GNC Faces Shareholder Class Action After Ore. AG Suit
- Fresenius Beats FCA Suit Over Charging Free Excess Drugs
- Judge Bars Supplement Co. From False Ads In FTC Suit
- Merck Slams Discovery Bid In $250M Sex Bias Suit
- 9th Circ. Won't Rehear Oakland's Bid To Keep Pot Shop Open
- Theranos Scrutiny Shows FDA's Murky Oversight Of Lab Tests
- Court Rescinds Venable Sanction In Abbott Birth Defect Row
- Claim Construction's Journey In The 9 Months Since Teva
- The Latest Unsuccessful Inter Partes Review Petitions
- Genentech Dodges FCA Claims Over Avastin's Side Effects
- Venable Sanctioned For Trial Delay In Abbott Birth-Defect Suit
- Pharma Exec's Indictment Shows DOJ Not Bluffing
- How A Pfizer-Allergan Deal Would Rank Among 2015's Largest
- Walgreens Offers Rite Aid Up To $650M In Breakup Fees
- New Del. Law Can't Invalidate Genelux Stock, Court Says
- Taylor-Wharton Gets Nod For Quick Ch. 11 Auction
- Fed. Circ. Says Atlas WiFi Patent May Be Invalid
- Biotech Co. Claims Ex-Partner Stole Research For Chemo Drug
- Frazier Healthcare Closes $262M Life Sciences Fund
- Retailers Tell Court Not To DQ 12 Firms In Lidoderm MDL
- AstraZeneca Says Dr. Reddy's Heartburn Pill Can't Be Purple
- MyoKardia Raises $54M In Latest Discounted Biotech IPO
- Dow Must Pay $456M To Bayer In Plant Patent Row
- Calif. High Court Rejects Takeda Appeal Of $6M Actos Verdict
- Feds End Bristol-Myers FCPA Probe After $14M SEC Fine
- Myriad In Australia Vs. Myriad In The US
- Ex-Warner Chilcott Exec Charged In Kickback Scheme
- J&J Says Client-Attorney Friendship Dooms Sunscreen Action
- Allergan Confirms Deal Talks With Pfizer
- Novartis Snags Atty Fees From Webvention In Patent Fight
- 5 Law Firms That Inspire Fear With Their Marketing Mojo
- 7 Takeaways As Industries Clash Over 340B 'Mega-Guidance'
- Supplement Co. Can't Get Atty Sanctions In False Ad Suit
- Settlement Lessons From Key Players In Guidant MDL
- Zimmer Ruling Continues Pa. Justices' Pro-Plaintiff Trend
- The Firms Behind Walgreens' $17.2B Rite Aid Play
- Medical Device Co. Must Reinstate Chairman, Court Says
- Bargaining Power Key To Walgreens, Rite Aid Merger Review
- Zimmer Undoes Jury's 'Excessive' $9.2M Hip Implant Verdict
- FTC Says FDA Biosimilar Naming Rules May Confuse Doctors
- Boston Scientific Settles $34.5M Pelvic Mesh Suit In Texas
- PTAB Upholds ImmunoGen's Breast Cancer Drug Patent
- Insurer Rips Tyco For Delays In $60M Drug Heist Suit
- FDA Warns Novartis Over Violations At Indian Drug Plants
- TriReme Takes $20M Catheter IP Loss To Fed. Circ.
- Abbott, AbbVie Urge No Punitive Damages In Depakote Suit
- Dow And Teva: Indefiniteness Defense Can Be Powerful
- FDA Warning Wire: Theranos, Temperature Devices, Sutures
- P&G Gets Stay Of Probiotic Class For High Court Review
- All Eyes On DOJ As Novartis FCA Deal Takes Shape
- Pa. Justices Say $20M Zimmer Verdict Was Wrongly Voided
- Kyle Bass Group Gets PTAB To Review 2 Celgene Patents
- Taylor-Wharton Slams Objections To Its DIP Package
- Allergan Says Court Botched Facts In Botox Antitrust Suit
- Pro Bono: The New Associate's Compass To Success
- First Quality Wants Another Antitrust Shot In Diaper IP Row
- PTAB Again Denies Review Of Merck Anti-Nausea Drug
- Judge Refuses To Recuse Himself In Diet Pill Sanctions Row
- Shire Tells Fed Circuit It Erred In Generic Vyvanse Suit
- Novartis Inks $390M FCA Deal Over Pharmacy Discounts
- TPP Biologics Exclusivity Period Maintains The Status Quo
- Judge Orders Arrest Of Brothers In NuScience IP Row
- 6 New Developments In Valeant's Specialty Pharmacy Saga
- FDA Panel Backs AstraZeneca Gout Drug Amid Dosage Concerns
- DOJ Subpoenas Valeant Over Bausch & Lomb Payments
- 3rd Circ. Allows RICO Class Suit Against GSK Over Avandia
- Allergan Breast Implant Suit Can Be Amended, 9th Circ. Says
- Consumers Push For Dismissal In Eli Lilly Cymbalta Case
- Baxter Says Talks With Brokerage Firm Are Privileged
- Taylor-Wharton Unsecured Creditors Rip 'Egregious' DIP Loan
- Vitamin E User Says Calif. Rulings Keep CVS Suit Alive
- Kyle Bass-Backed Group Gets PTAB To Review Gattex Patent
- Viagra Increases Risk Of Developing Melanoma, Suit Says
- Proskauer Settles J&J Heir's Suit Claiming Faulty Tax Advice
- Risperdal Caused Autistic Boy's Breast Growth, Pa. Jury Told
- Zimmer Asks For Win In 1st Knee-Impant Bellwether Trial
- Biotech Co. Asks High Court To Enter Patent License Fray
- Refresh Or Rebuild? Website Strategies For Big Law
- Allegation Of Willful Infringement May Get Its Bite Back
- Justices Urged To Not Review Biolitec $70M Contempt Ruling
- EX-CFR Director Makes $13.2M Deal In Insider Trading Suit
- Spectrum To Confer With FDA On Cancer Drug Approval Delay
- Fired Bio-Rad GC Hangs On To Most Whistleblower Claims
- Pa. Judge Defends Barring Punitives At Risperdal Trials
- Are Patient Advisers Contraindicated For Pharma Cos.?
- Knee Implant Patient Testifies In 1st Zimmer Test Trial
- Mylan Argues IRS Can't Keep $100M Tax Dispute From Trial
- Shire Still Pushing For $30B Baxalta Deal
- Kansas City Fed Rejects Colorado Pot Credit Union
- Valeant Hit With Investor Suit Over Pharmacy Ties
- House Passes Bill To Repeal Key ACA Mandates
- Reining In FTC's Crusade Against Dietary Supplements
- Where We Stand On Pharmaceutical Patent Settlements
- Abbott Hits Back At Infant Formula False Ad Claims
- Calif. Marijuana Co. Owes Tax Under Federal Trafficking Law
- Zyprexa Liability Suit Belonged In State Court, 7th Circ. Says
- J&J Claims Prejudice Marred 1st Philly Risperdal Case
- FDA Adds Liver Safety Warning To AbbVie Hepatitis C Drugs
- Actos Buyers Head To 2nd Circ. After Pay-For-Delay Suit Nixed
- Fired Teva Atty Asks Court To Resuscitate Defamation Claim
- Adderall Buyers Defend Expert Report Deemed Late By Shire
- Biomet Faces $10M Retaliation Suit Over Alleged Kickbacks
- Perrigo Aims To Thwart 'Terrible' Mylan Deal With $2B Buyback
- Wyeth Should Face Drug Rebate Claims In Court, States Say
- FDA Approved 'Sham' Label For Cancer Drug, DC Circ. Told
- Why More Businesses Are Considering The B Corp. Model
- Bayer Tells 8th Circ. It Doesn't Owe $9M Fees In GMO Suit
- Don't Forget Child Sites Under The 340B Omnibus Guidance
- 8 Regulatory Considerations For Digital Health Care Cos.
- 1st Circ. Won't Ask Mass. High Court For Help In VisionAid Suit
- Daiichi, Mylan Push High Court To Hear Apotex Drug IP Fight
- Sperm Bank Defeats Negligence Suit Over Ex-Felon's Sample
- Valeant Sent Reeling By Phantom-Sales Allegations
- J&J Unit Can't Escape Idaho Woman's Vaginal Mesh Suit
- Trial Will Be About Fake Drugs, Not Homeopathy, Class Says
- 23andMe Reintroduces DNA Health Test With FDA Blessing
- An Update On Section 101 Rejection Rates At The USPTO
- FDA Expresses Safety Concerns Over AstraZeneca Gout Drug
- P&G Urges Stay Of Probiotic Class For High Court Review
- Apotex Sets Stage For Next Fed. Circ. BPCIA Dispute
- 4 Reasons To Use Electronic Deposition Exhibits
- Payroll Tax Breaks Save San Francisco Cos. $44M: Report
- Medtronic Cleared Of NuVasive Design Patent Claim
- Allergan Can't Escape Botox Antitrust Suit
- GCs Brace For Shift In State AGs Priorities
- Goodwin Procter Nabs Tech Pro For Silicon Valley Office
- US Government Hit With Suit Over Vaccine Contract Payment
- Sequenom's 'Sky Is Falling' Claims Blasted In DNA Patent Row
- Health Care Firm Hall Render Opens Seattle-Area Office
- 4 Things You Should Never Say To An Associate
- Stryker Fights For $8.6M Implant Coverage Win In 6th Circ.
- Merck Must Hand Over Payment, Job Data In Sex Bias Suit
- Sigma-Aldrich Sells Chemicals Biz Amid $17B Merck Takeover
- PTAB Denies Another Kyle Bass Petition For Drug Review
- Cymbalta Claims Too Different For Class Actions, Judge Says
- Otsuka Sues FDA Over Approval Of Abilify Maintena Rival
- Stroke Prevention Co. Gets $57M Injection From Backers
- Pa. Women Gets 2.5 Years For Selling Banned Diet Drugs
- Issues Facing Life Sciences Cos. After EU-US Safe Harbor
- 23andMe Can't Kibosh Classwide Arbitration In False Ad Row
- Purchasers Win Cert. Again In Blood Test Antitrust MDL
- J&J Unit Hit With $5.6M Verdict Over Calif. Risperdal Death
- High Court Cases Could Clear Way For Bigger Patent Damages
- Anda Appeals 'Pill Mill' Coverage Loss to 11th Circ.
- J&J Tells High Court $140M Motrin Label Verdict Can't Stand
- FDA Delays OKing Shire's Eye Drug As Baxalta Bid Dangles
- Biogen Attacks Bass Group's AIA Review Bid For MS Drug
- NC Jury Hands Boston Scientific Win In Pelvic Mesh Case
- Ex-Access CEO Loses Bid For House Arrest In Fraud Case
- Taylor-Wharton Unsecured Creditors Blast 'Warp-Speed' Sale
- Amgen Calls For Halt To Neulasta Biosimilar Marketing
- Fed. Circ. Affirms $4M Trade Secrets Verdict Against Globus
- Perrigo, Mylan Want Retractions In $27B Hostile Bid Fight
- Jurisdiction In Hatch-Waxman Actions Against Foreign Entities
- OPINION: The Bitter Pill Of Competition Within Large Law
- Justices To Review Standard For Willful Patent Infringement
- Propofol Injury Suit Still Must Prove Teva Has Florida Ties
- Adderall Antitrust Class Has Standing Questioned At Trial
- Homeopathic Co. Says Buyers Bear Burden At Upcoming Trial
- FDA Holds Off Approval Of AstraZeneca Diabetes Treatment
- 4 Questions After Amgen-Sandoz Rehearing Bids Fizzle Out
- Perrigo Ex-Worker Pushes Back On Nixed FCA Drug Claims
- FDA Removes Pacira Warning Letter Amid Free Speech Suit
- J&J Wins First Tylenol Liver Damage Trial
- Former Boston Scientific Atty Joins Baker Sterchi
- PTAB Again Rejects Kyle Bass AIA Review Bid Of Drug Patent
- Is A Medical Device Cyber Vulnerability A Design Defect?
- Calif. Medical Pot Shops Fight IRS Write-Off Bans
- Feds Slam Ex-Access CEO's Bid For 6-Months House Arrest
- Momenta, Sandoz Sought Clot Drug Monopoly, Suit Says
- Fed. Circ. Won't Rehear Amgen-Sandoz Biosimilar Dispute
- TriReme Fears Bankruptcy After $20M Catheter Row Loss
- Ferring's Muted Fertility Drug Recall Falls Within FDA Rules
- 4 Issues To Watch After 340B Orphan Drug Ruling
- Suits Alleging Ethicon Device Spreads Cancer Consolidated
- Endo Lobbies For Dismissal Of Painkiller Pay-For-Delay Suit
- NexGen Patient Presses Zimmer In 1st MDL Test Trial
- Otsuka Loses Fee Bid In Abilify Patent Suit
- J&J's Marketing Of Risperdal For Children Slammed In Trial
- Ex-Access CEO Asks For House Arrest To See Kids Graduate
- Sen. Turns Up Heat As WTO Discusses Drug Patent Waiver
- Drugmaker Wants 12 Firms Booted From Pay-For-Delay MDL
- Metadata 101 For Lawyers: A 2-Minute Primer
- Valeant Says Feds Probing Its Financial Assistance Program
- Teva's $512M Provigil Deal Looks Good To Judge
- Exeltis Sues Acella Over Alleged Drug Trade Secrets Theft
- Homeopathic Co. Says False Ad Suit Lacks Evidence
- 3rd Circ. To Hear Appeal Of Cert. In Provigil Antitrust Row
- 340B Orphan Drug Discounts Dialed Back
- Consumers Pulling A Fast One In Cymbalta Case, Eli Lilly Says
- Avon Buyers Take Class Bid In False Ad Suit To 2nd Circ.
- Taro Infringed Schizophrenia Drug Patents, Suit Claims
- Amgen Can't Enforce Biosimilar Law, Hospira Says
- Bayer Says Woman's Mirena Claims Are Time-Barred
- Ex-Gov. McDonnell Takes Bribery Fight To High Court
- Ex-Access CEO Gets 3.5 Years For Fraud, Tax Evasion
- Hospira To Pay $400K Back Wages In Hiring Bias Case
- Body Part Snatching Case Should Go To Trial, Relatives Say
- NY AG Opens Antitrust Inquiry Into Turing Drug Practices
- Supplement Co. Wants FTC Attys Booted From Labeling Suit
- Insurer Refuses To Cover Workout Supplement Injury Suits
- GSK Says FDA Orders Nix Reed Smith Atty's Widow's Claims
- High Court Denies Hollister Ex-Beneficiaries' ERISA Appeal
- JPML Consolidates Birth Defect Suits Over GSK's Zofran
- Cryogenics Co. Gets Interim Approval To Tap $14M DIP
- FDA Warning Wire: Bird Poop, Ebola, Hello Kitty
- Dozens Of Pelvic Mesh Suits To Join J&J MDL In W.Va.
- Food Safety Co. Knew Of Problems Before IPO, Investors Say
- FDA Stalls On Collegium's 'Abuse-Deterrent' Painkiller
- Wal-Mart, Others Blast FCA Suit Alleging They Sold Old Meds
- Enzo Reaches $10M Deal With Affymetrix To End Patent Row
- CORRECTED: Helsinn, Dr. Reddy's Settle Patent Suit Over Generic Aloxi
- Epstein Becker Grabs SAIC, Miller Canfield Technology Pros
- Nutraceutical Wants Proposed 'Sugar Pill' Class Action Nixed
- Bristol-Myers Settlement: A Strong Warning To Joint Venturers
- Calif. OKs Nation's Toughest Limits On Livestock Antibiotics
- Eli Lilly Beats 2nd Consolidation Bid In Cymbalta Litigation
- Roche Pays $580M For Biotech Developing Arthritis Treatment
- UK Watchdog Puts Conditions On Reckitt, K-Y Deal
- Inovio Beats Former Pharma Exec's Stock Options Suit
- Hi-Tech Fights $35M FTC Contempt Motion in Supplement Suit
- WikiLeaks Releases Secret Text Of TPP's IP Section
- Helsinn, Roche Sue Over Planned Generic Of Nausea Drug
- FDA's Abilify Smack-Down Boosts Imitator Drugs
- 10 Ways To Become A 360-Degree Lawyer
- $100M Boston Scientific Mesh Verdict Slashed To $10M
- Obama's FDA Nominee Too Close To Big Pharma: Sanders
- Drug Antitrust Issues With Daraprim And Beyond
- Pa. Hospital Urges Class Cert. In Med Supply Antitrust Row
- Phishing For Coverage: When Is Fraud A 'Computer Fraud'?
- Impossibility Preemption Is Possible In 510(k) Device Cases
- Watchdog Verifies FDA Review Of Disputed Device Approvals
- Pfizer Beats Zoloft Birth Defect Suit In Philadelphia
- Reed Smith Atty's Widow Fights GSK's Bid To Nix Suicide Suit
- Ex-Access CEO Deserves 4 Years For Fraud, Feds Say
- Takeda Strikes Possible Deal, Halts Nev. Actos Cancer Trial
- Biotech CEO Backpedals On Guilty Plea For Funneling Shares
- Amicus Faces Shareholder Suit Over Rosy NDA Statements
- Sheller To Appeal Suit Over FDA Inaction On Risperdal Docs
- Price Hike Scrutiny May Land Drug Cos. In Antitrust Hot Water
- Hedge Fund Group Gets Review Of Bowel Disease Drug Patent
- Supplements Falsely Marketed As Steroids, Suit Says
- Cytomx Prices IPO Below Range As More Biotechs Scale Down
- Taylor-Wharton Ch. 11 Auction Proposal Put On Fast Track
- Finance Chairman Bristles At TPP's Drug, Tobacco Provisions
- The Retrospective Approach To Companion Diagnostics
- Colo. Pot Credit Union Says No Trial Needed In KC Fed Case
- Blackstone Inks $8B Deal For Health Care REIT
- GSK Rips 'Junk Science' By Reed Smith Atty Widow's Expert
- Celgene Trying To Skirt $700M In FCA Claims, Relator Says
- J&J Says It's Being Harassed During Mesh MDL Discovery
- Hausfeld, Others To Helm Contact Lens Antitrust MDL
- Novartis Ducks Zometa Failure-To-Warn Suit
- Jury Verdict Sinks False Ad Class, Hyland's Tells Judge
- Amazon, GNC, Others Sued Over Workout Supplements
- Wyeth, Abbott Agree To Dismiss Suit Over Stent Patents
- Colo. Judge Tosses 'Convoluted' Genzyme Class Action
- SIGA Asks Del. Justices To Ax $195M PharmAthene Ruling
- FDA Launches Crackdown On Allergy Treatments Labeling
- FTC Steris-Synergy Merger Challenge Halted After Court Loss
- PharMerica Inks $9M FCA Deal Over Kickback Allegations
- FINRA Bans Firm, CEO Over Cancer Drug Kickback Scheme
- Zimmer Rips Bellwether Delays In Knee Implant MDL
- Fox Rothschild Adds Pharma Compliance Pro To NJ Office
- Some Useful Insights From Steris-Synergy Merger Case
- Celgene Can't Limit Claims In FCA Off-Label Marketing Row
- FDA Warning Wire: Salsa, Concussion Relief, Drugged-Up Cow
- MedTel24 In Contempt Of Heart Monitor Patent Order
- Calif. Woman Sues Biomet Claiming Hip Replacement Defects
- 5th Circ. Shouldn't Rehear Toe Implant Fight, Patient Says
- GSK, Teva To Take Lamictal Pay-For-Delay Case To High Court
- Hi-Tech Asks Judge For Recusal Over Seeing Privileged Docs
- Apotex Accuses Amgen Of Sham Patent Litigation
- J&J Win In Children's Motrin Suit Offers New Trial Tactic
- 5 Things Clients Never Tell Their Lawyers
- Allergan Beats Miotox's $600M Botox Royalty Claims
- Cutoff Date Set For Collective Notice In $100M Sex-Bias Suit
- Prograf Class Cert. Makes Case Unworkable, 1st Circ. Hears
- Texas Court Won't Revisit $2M Drug License Arbitral Award
- TPP Compromises Set Stage For Political Standoff
- Nexium Buyers Get $8M Fees In Pay-For-Delay Settlement
- Engaged Capital Protests $857.8M HeartWare-Valtech Deal
- Supreme Court Rejects $1B Gore Patent Suit
- J&J Wins 1st Trial Over Prosima Pelvic Mesh
- AbbVie Docs Not Privileged In Pay-For-Delay Suit, FTC Says
- Bristol-Myers Squibb Pays $14M Over Alleged China Bribes
- 7th Circ. Stands Out On Ascertainability Of Class Actions
- Acacia Unit Settles Medical Patent Suits With CR Bard
- Abbott, Plaintiffs Limit Expert Testimony In Depakote Trial
- Boston Scientific Ducks Pacemaker Defect Suit Under Riegel
- Reckitt Loses Reconsideration Bid In Mucinex Antitrust Row
- Fed. Circ. Says Sandoz Didn't Infringe Cancer Drug Patent
- Midmarket IPO Activity Drops In Q3 But Offers Sizes Grow
- Pfizer Gets Plaintiffs' Expert Blocked In Zoloft Trial
- Jury Asked To Award $9.5M Damages In J&J Pelvic Mesh Case
- Insurer Refuses Coverage For USPlabs In Diet Pill Suits
- FTC's False Ad Claims Against Bayer Baseless, Judge Says
- Amgen Gets Failure-To-Warn Claims Axed From Enbrel Suit
- Sandoz Files Application For Biosimilar To Amgen's Enbrel
- Proskauer-Led NovoCure Raises $165M In Downgraded IPO
- The Minefield Of E-Cigarette Labeling And Promotion
- Ethicon Plaintiffs' Attys Grilled On MDL Consolidation
- GSK Must Face Paxil Liability Suit
- FTC Ending Court Bid To Block $1.9B Steris-Synergy Deal
- Mylan Infringed Cumberland's Acetadote Patent, Judge Rules
- Paul Weiss Must Pony Up Privileged Docs On Defunct Med Co.
- Eisai Loses Bid For Longer Exclusivity In FDA Delay Fight
- Judge Clears Boston Scientific In $200M Stent Patent Case
- 5th Circ. Lets Supplement Maker Sue Texas AG In Label Row
- FTC Pushes 3rd Circ. To Revive Doryx Product-Hopping Case
- Specialty Pharmacy Market Ripe For Private Equity Buyers
- Valeant Hits Apotex With Patent Suit Over Colitis Drug
- Pa. Court Won't Revive $20M Suit Over Skin Drug Patents
- Jones Day Adds Ex-K&L Gates Partner To Pittsburgh Office
- SEC Gets $7M Judgment In Pharma Pump-And-Dump Scheme
- Teva Boosts Presence In Mexico With $2.3B Rimsa Buy
- How Fed. Circ. Views Obviousness-Type Double-Patenting